New Leaf Venture Partners Names Milton B. McColl, M.D. as Venture Partner
NEW YORK & MENLO PARK, Calif. – April 16, 2007 – New Leaf Venture Partners (NLV Partners) announced today the appointment of Milton B. McColl, M.D. as a venture partner. Dr. McColl most recently served as President of Boston Scientific’s Neurovascular division. Dr. McColl’s appointment is effective immediately, and he will be based in NLV Partners’ West Coast office, located in Menlo Park, CA.
Jeani Delagardelle, Managing Director at NLV Partners, stated, “Milt has a strong track record of success in senior leadership roles in diverse settings, from Boston Scientific to early-stage device companies, and he has served as president of a Stanford University-affiliated investment fund for the past decade. He even had a leadership role on the playing field as a two-time Super Bowl and World Champion in the 1980s.”
Dr. McColl commented, “I am pleased to join the NLV team as they continue to build their strong franchise in healthcare technologies. My background on the operational side and my experience in healthcare investing should complement well the skill sets of the talented people at NLV.”
Ms. Delagardelle added, “Milt’s expertise will be invaluable to the efforts of young start-up companies in our portfolio as they advance promising platforms towards the market and successful commercialization. We think Milt will be a tremendous asset, and we are delighted that he is joining NLV Partners.”
Dr. McColl’s tenure with Boston Scientific began in 2001. At that time, he was serving as Vice President of Clinical, Regulatory and Quality and Medical Director of Embolic Protection, Inc., a company acquired by Boston Scientific. Following the acquisition, Dr. McColl served as Vice-President and General Manager for Boston Scientific’s Embolic Protection franchise and subsequently was promoted to president of the company’s neurovascular division.
Prior to this, Dr. McColl was the President and Chief Executive Officer of Genitope, Inc., and President and Chief Executive Officer of CSFluids, Inc. (later renamed Eunio). Previous positions also included Vice President of Regulatory, Quality, &, Clinical Affairs and Chief Medical Officer for Gynecare, Inc. and Director of Marketing of Origin Medsystems.
Since 1997, Dr. McColl has also served first as president and then as Executive Board Member for the Stanford University DAPER Investment Fund, a unique Venture Capital and other investment vehicle fund benefiting the Stanford University Department of Athletics.
Dr. McColl earned his B.S. degree in biology from Stanford University and his M.D. degree from Stanford University School of Medicine. Dr. McColl also had a career as a professional football player with the San Francisco Forty Niners and Los Angeles Raiders in the 1980s, during which time he was twice a Super Bowl and World Champion.
About NLV Partners
New Leaf Venture (NLV) Partners is a life science-dedicated venture capital firm with offices in Menlo Park and New York. Founded by an experienced team of venture capitalists with deep healthcare industry experience, NLV Partners invests primarily in companies focused on clinical-stage biopharmaceutical products, early-stage medical devices, and molecular diagnostics. NLV manages over $1 billion of assets including its NLVI Fund as well as the existing healthcare technology portfolio of Sprout Group (under a sub-management contract). More information is available at www.nlvpartners.com .
Burns McClellan on Behalf of NLV Partners
Justin Jackson, 212-213-0006, ext. 327, email@example.com